Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Director | February 06, 2023 | February 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date February 06, 2023 · Filed February 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,046 |
Reported balance
After 2023-02-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-06 · Exercise / conversion · Acquired 12,000 · Balance 142,046 F1: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2023-02-06 | Direct | 0 |
Reported balance
After 2023-02-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-06 · Exercise / conversion · Disposed 12,000 · Balance 0 F2: The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person.
F2: The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2023 Filed Feb 8, 2023 11:03 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001104659-23-012103 · tm235846-1_4seq1.xml · derivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2023-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 11:03 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 12,000 | $2.65 | $31,800.00 |
DisclosureSEC source: 0001104659-23-012103 · tm235846-1_4seq1.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 22:50 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 37,950 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001104659-22-090257 · tm2223355-6_4seq1.xml · derivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,950 Underlying: Common Stock · 37,950 shares Expires 2032-08-10 F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| May 06, 2022 Filed May 9, 2022 20:13 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 5,000 | $1.96 | $9,795.00 |
DisclosureSEC source: 0001104659-22-057514 · tm2214932-1_4.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,046 F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 60,746 shares of common stock owned by the reporting person, inclusive of the 5,000 shares of common stock purchased in the open market and reported on this Form 4. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001104659-21-112499 · tm2126875-1_4seq1.xml · derivative · entry 3 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2022-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 4,000 | $9.40 | $37,591.20 |
DisclosureSEC source: 0001104659-21-112499 · tm2126875-1_4seq1.xml · nonDerivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,046 F1 · price: Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 4,000 | $4.13 | $16,500.00 |
DisclosureSEC source: 0001104659-21-112499 · tm2126875-1_4seq1.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 15, 2021 01:16 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 34,500 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001104659-21-050401 · tm2113016d7_4.xml · derivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires 2031-04-12 F1 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options will vest in four equal parts on 4/12/2021, 6/30/2021, 9/30/2021 and 12/31/2021, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-20-124504 · tm2035834-1_4.xml · derivative · entry 3 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2021-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were originally granted to Mr. Kraus on January 6, 2011 as compensation for services rendered. The grant became fully vested on January 6, 2020. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 8,000 | $8.00 | $64,000.00 |
DisclosureSEC source: 0001104659-20-124504 · tm2035834-1_4.xml · nonDerivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,046 F1 · shares: These shares were sold in multiple transactions and multiple lots for the same price for this sale have been combined. F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:31 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 8,000 | $3.45 | $27,600.00 |
DisclosureSEC source: 0001104659-20-124504 · tm2035834-1_4.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0001104659-20-028655 · tm2011575d7_form4.xml · derivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-28 F1 · derivative.exercise_date: Includes 30,000 stock options granted on 2/28/2020 and reported on this Form 4. These options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and will vest in four equal parts on 3/31/2020, 6/30/2020, 9/30/2020 and 12/31/2020. F1 · balance_after: Includes 30,000 stock options granted on 2/28/2020 and reported on this Form 4. These options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and will vest in four equal parts on 3/31/2020, 6/30/2020, 9/30/2020 and 12/31/2020. Read SEC document |
| July 22, 2019 Filed Jul 25, 2019 00:17 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001144204-19-035840 · tv525806_4.xml · derivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-07-22 F1 · derivative.exercise_date: Such options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and vest in four equal parts at the end of each calendar quarter. The grant gives effect to vesting which was to occur on March 31, 2019 and June 30, 2019. The remaining portion of the grant will vest on September 30, 2019 and December 31, 2019. Read SEC document |
| August 30, 2018 Filed Sep 1, 2018 00:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001144204-18-047656 · tv502207_4.xml · derivative · entry 5 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2019-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options issued to the reporting person became exercisable according to the following vesting schedule: 4,500 stock options vested on 1/28/2009; 4,500 stock options vested on 1/28/2010; 4,500 stock options vested on 1/28/2011; and 4,500 stock options vested on 1/28/2012. Read SEC document |
| August 30, 2018 Filed Sep 1, 2018 00:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001144204-18-047656 · tv502207_4.xml · derivative · entry 4 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2019-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Sep 1, 2018 00:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 26,000 | $14.47 | $376,282.40 |
DisclosureSEC source: 0001144204-18-047656 · tv502207_4.xml · nonDerivative · entry 3 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,046 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.605. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes (a) the following restricted stock units subject to vesting upon a "Change in Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 55,746 shares of common stock owned by the reporting person. Read SEC document |
| August 30, 2018 Filed Sep 1, 2018 00:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 18,000 | $4.20 | $75,600.00 |
DisclosureSEC source: 0001144204-18-047656 · tv502207_4.xml · nonDerivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Sep 1, 2018 00:19 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 8,000 | $2.10 | $16,800.00 |
DisclosureSEC source: 0001144204-18-047656 · tv502207_4.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Apr 27, 2018 15:45 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 28,875 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001144204-18-022972 · tv492279_4.xml · derivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,875 Underlying: Common Stock · 28,875 shares Expires 2028-03-15 F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018. Read SEC document |
| March 15, 2018 Filed Apr 27, 2018 15:45 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-022972 · tv492279_4.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,046 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). F2 · balance_after: Includes (a) the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (i) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 55,746 shares of common stock owned by the reporting person. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001144204-17-011817 · v460704_4.xml · derivative · entry 2 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-02-24 F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011817 · v460704_4.xml · nonDerivative · entry 1 Kraus Al · CIK 0001368152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,746 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan. F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 5,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above, (iii) 55,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (1) above and (iv) 55,746 shares of common stock owned by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.